Safety · source year
11 selected, source-linked safety and enforcement records dated 2026. This is selective source coverage, not a complete timeline.
11 selected records.
6 connected profiles.
11 distinct public records.
Cited chronology
Glucagon
FDA's dated enforcement report D-0723-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA214457 through exact openFDA application-number annotations.
Semaglutide + 1 more
FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026.
Liraglutide
FDA's dated enforcement report D-0541-2026 lists Class II and source status Ongoing for Lupin Pharmaceuticals Inc. PeptideScanner connects the report to reviewed application ANDA215421 through exact openFDA application-number annotations.
Octreotide
FDA's dated enforcement report D-0519-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
Lanreotide
FDA's dated enforcement report D-0422-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.
Lanreotide
FDA's dated enforcement report D-0423-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application ANDA217193 through exact openFDA application-number annotations.
Octreotide
FDA's dated enforcement report D-0404-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
Octreotide
FDA's dated enforcement report D-0405-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
Octreotide
FDA's dated enforcement report D-0406-2026 lists Class II and source status Ongoing for Teva Pharmaceuticals USA, Inc. PeptideScanner connects the report to reviewed application ANDA210317 through exact openFDA application-number annotations.
Lanreotide
FDA's dated enforcement report D-0290-2026 lists Class II and source status Ongoing for Cipla USA, Inc. PeptideScanner connects the report to reviewed application NDA215395 through exact openFDA application-number annotations.
Semaglutide + 2 more
FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.